All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AAV-mediated gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: UCB Pharma S.A.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 12, 2020
Details:
New collaboration with Lacerta Therapeutics underlines UCB’s strategic focus in gene therapy to fulfil its Patient Value Ambition. New R&D collaboration with Lacerta Therapeutics provides access to a novel gene therapy program and proprietary AAV capsids.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: $2,100.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration October 28, 2020
Details:
Insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will be responsible for clinical development and regulatory submissions and commercialization activities.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: $2,150.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration October 28, 2020
Details:
insitro will apply insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will have the option to select a number of targets identified by insitro to advance through clinical development and commercialization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $8.0 million Upfront Cash: Undisclosed
Deal Type: Funding October 08, 2020
Details:
Knopp has developed a discovery platform of molecules directed to a non-opioid biological target linked to chronic pain caused by nerves damage. The drug target is Kv7.2/7.3 which regulates the flow of electrically charged ions required to modulate the excitability of cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Antibody therapeutics
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Casdin Capital
Deal Size: $25.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 29, 2020
Details:
The Series A Financing positions the company for rapid scaling of its novel platform and advancing its portfolio of innovative antibody therapeutics for veterinary use.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund
Deal Size: $29.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 23, 2020
Details:
The company’s therapeutic platform is uniquely positioned to discover and develop novel small molecule drugs that can both increase autophagy to more rapidly clear toxic proteins and attenuate the production of neurotoxic proteins.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Mitochondria therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Axil Capital Partners
Deal Size: $9.8 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 01, 2020
Details:
LUCA Science is developing an innovative platform of highly functional mitochondrial using proprietary technologies. LUCA Science’s mitochondria can be stored and delivered as a biopharmaceutical agent.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ADX10061
Therapeutic Area: Neurology Product Name: ADX10061
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Innosuisse
Deal Size: $0.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 27, 2020
Details:
CHF600K Innosuisse grant will support SIB's computational approaches to identify new therapeutic indications for ADX10061, a potent and selective dopamine D1 receptor antagonist.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: The Column Group
Deal Size: $73.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing July 29, 2020
Details:
Nura Bio seeks to alter the course of neurological disease by targeting the fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Orexia Limited
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 22, 2020
Details:
After successfully reaching this development milestone in the collaboration, Orexia exercised an option to exclusively license the orexin receptor type 2 (OX2R) program from X-Chem, which comprises multiple novel OX2R-specific small molecule orexin positive modulators.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
